{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:29:19Z","timestamp":1789540159258,"version":"build-2803163510"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.tube.2023.102367","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T21:14:47Z","timestamp":1688505287000},"page":"102367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility"],"prefix":"10.1016","volume":"141","author":[{"given":"Rinu Mary","family":"Xavier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Sharumathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Kanniyappan Parthasarathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepalakshmi","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharani","family":"Mohanasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2023.102367_bib1","unstructured":"World Health Organization Tuberculosis 2022. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tuberculosis 27\/10\/2022, accessed on 28\/03\/23]."},{"issue":"9","key":"10.1016\/j.tube.2023.102367_bib2","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/infdis\/jit352","article-title":"Serum drug concentrations predictive of pulmonary tuberculosis outcomes","volume":"208","author":"Pasipanodya","year":"2013","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.5588\/ijtld.15.0803","article-title":"Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis","volume":"20","author":"Mota","year":"2016","journal-title":"Int J Tubercul Lung Dis"},{"issue":"8","key":"10.1016\/j.tube.2023.102367_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40265-014-0222-8","article-title":"Therapeutic drug monitoring in the treatment of tuberculosis: an update","volume":"74","author":"Alsultan","year":"2014","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.tube.2023.102367_bib5","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1378\/chest.120.5.1520","article-title":"Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy","volume":"120","author":"Mehta","year":"2001","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.tube.2023.102367_bib6","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/429321","article-title":"Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis","volume":"40","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2023.102367_bib7","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1086\/599040","article-title":"Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana","volume":"48","author":"Chideya","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.tube.2023.102367_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/cid\/cis353","article-title":"Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy","volume":"55","author":"Pasipanodya","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.tube.2023.102367_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TNMI7-0029-2016","article-title":"The role of therapeutic drug monitoring in mycobacterial infections","volume":"5","author":"Peloquin","year":"2017","journal-title":"Microbiol Spectr"},{"issue":"12","key":"10.1016\/j.tube.2023.102367_bib10","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.ejca.2014.04.014","article-title":"Review of therapeutic drug monitoring of anticancer drugs part 1-cytotoxics","volume":"50","author":"Paci","year":"2014","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.tube.2023.102367_bib11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.ftd.0000211810.19935.44","article-title":"Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants","volume":"28","author":"Ting","year":"2006","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.tube.2023.102367_bib12","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40262-019-00763-3","article-title":"Optimal sampling strategies for therapeutic drug monitoring of first-line tuberculosis drugs in patients with tuberculosis","volume":"58","author":"Saktiawati","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.tube.2023.102367_bib13","first-page":"392","article-title":"Limited-sampling strategies for anti-infective agents: systematic review","volume":"62","author":"Sprague","year":"2009","journal-title":"Can J Hosp Pharm"},{"issue":"19","key":"10.1016\/j.tube.2023.102367_bib14","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.4155\/bio.12.244","article-title":"Interview: challenges faced by the modern bioanalytical laboratory","volume":"4","author":"Sangster","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.tube.2023.102367_bib15","first-page":"4","article-title":"Optimal sampling times for therapeutic drug monitoring","volume":"S1","author":"van der Meerm","year":"2012","journal-title":"Adv Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.tube.2023.102367_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/157339409787314081","article-title":"Utility of limited sampling strategies for anticancer agents in the clinical arena: a systematic review","volume":"5","author":"Pattar","year":"2009","journal-title":"Curr Cancer Ther Rev"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ebnurs-2021-103425","article-title":"Understanding and interpreting regression analysis","volume":"24","author":"Ali","year":"2021","journal-title":"Evid Base Nurs"},{"issue":"9","key":"10.1016\/j.tube.2023.102367_bib18","first-page":"439","article-title":"Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis","volume":"37","author":"Mahmood","year":"1999","journal-title":"Int J Clin Pharmacol Therapeut"},{"issue":"2","key":"10.1016\/j.tube.2023.102367_bib19","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007691-200104000-00003","article-title":"Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms","volume":"23","author":"David","year":"2001","journal-title":"Ther Drug Monit"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1046\/j.1472-8206.2002.00086.x","article-title":"Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs","volume":"16","author":"Rousseau","year":"2002","journal-title":"Fundam Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib21","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01240143","article-title":"Limited-sampling models for anticancer agents","volume":"120","author":"van Warmerdam","year":"1994","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.tube.2023.102367_bib22","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","article-title":"Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation","volume":"33","author":"van der Meer","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1016\/j.tube.2023.102367_bib23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00003088-200038050-00004","article-title":"Methods for clinical monitoring of cyclosporin in transplant patients","volume":"38","author":"Dumont","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.tube.2023.102367_bib24","series-title":"Simulation for designing clinical trials: a pharmacokinetic-pharmacodynamic modeling perspective","first-page":"73","article-title":"Determination of model appropriateness","author":"Williams","year":"2003"},{"issue":"3","key":"10.1016\/j.tube.2023.102367_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2165\/00003088-200746030-00003","article-title":"Are population pharmacokinetic and\/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004","volume":"46","author":"Brendel","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"14","key":"10.1016\/j.tube.2023.102367_bib26","first-page":"5068","article-title":"The importance of pharmacokinetic limited sampling models for childhood cancer drug development","volume":"9","author":"Panetta","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-200746060-00002","article-title":"A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy","volume":"46","author":"Loh","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.tube.2023.102367_bib28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00280-004-0896-9","article-title":"Development of a pharmacokinetic limited sampling model for temozolomide and its active metabolite MTIC","volume":"55","author":"Kirstein","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","article-title":"Some suggestions for measuring predictive performance","volume":"9","author":"Sheiner","year":"1981","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"10.1016\/j.tube.2023.102367_bib30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2125.2010.03815.x","article-title":"Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients","volume":"71","author":"Barraclough","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib31","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/FTD.0000000000000093","article-title":"Limited sampling strategies to predict the area under the concentration-time curve for rifampicin","volume":"36","author":"Medell\u00edn-Garibay","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.tube.2023.102367_bib32","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1128\/AAC.00756-15","article-title":"Pharmacokinetic modeling and optimal sampling strategies for therapeutic drug monitoring of rifampin in patients with tuberculosis","volume":"59","author":"Sturkenboom","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2023.102367_bib33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/jcpt.13098","article-title":"Limited sampling strategy for predicting isoniazid exposure in patients with extrapulmonary tuberculosis","volume":"45","author":"Alshaikheid","year":"2020","journal-title":"J Clin Pharm Therapeut"},{"key":"10.1016\/j.tube.2023.102367_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2021.102052","article-title":"Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis","volume":"127","author":"Lee","year":"2021","journal-title":"Tuberculosis"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41397-021-00223-x","article-title":"Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients","volume":"21","author":"Alshaikheid","year":"2021","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.tube.2023.102367_bib36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ijantimicag.2017.01.036","article-title":"Limited sampling strategies for determining the area under the plasma concentration-time curve for isoniazid might be a valuable approach for optimizing treatment in adult patients with tuberculosis","volume":"50","author":"Cojutti","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40262-020-00971-2","article-title":"Isoniazid precision dosing group. A model-informed method for the purpose of precision dosing of isoniazid in pulmonary tuberculosis","volume":"60","author":"van Beek","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00003-22","article-title":"Population pharmacokinetic modelling and limited sampling strategies for therapeutic drug monitoring of pyrazinamide in patients with tuberculosis","volume":"66","author":"Abolhassani-Chimeh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2023.102367_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijantimicag.2014.04.019","article-title":"Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin","volume":"44","author":"Magis-Escurra","year":"2014","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"10.1016\/j.tube.2023.102367_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01092-18","article-title":"Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients","volume":"62","author":"van den Elsen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib41","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1128\/AAC.00341-15","article-title":"Limited sampling strategy and target attainment analysis for levofloxacin in patients with tuberculosis","volume":"59","author":"Alsultan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2023.102367_bib42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0b013e31821b793c","article-title":"Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis","volume":"33","author":"Pranger","year":"2011","journal-title":"Ther Drug Monit"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib43","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00384-19","article-title":"Limited sampling strategies using linear regression and the bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients","volume":"63","author":"van den Elsen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib44","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","article-title":"Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis","volume":"49","author":"Kamp","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.tube.2023.102367_bib45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","article-title":"Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis","volume":"32","author":"Alffenaar","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.tube.2023.102367_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2015.06.008","article-title":"Limited sampling strategies for therapeutic drug monitoring of amikacin and kanamycin in patients with multidrug-resistant tuberculosis","volume":"46","author":"Dijkstra","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib47","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40262-020-00860-8","article-title":"Pharmacokinetic modeling, simulation, and development of a limited sampling strategy of cycloserine in patients with multidrug-\/extensively drug-resistant tuberculosis","volume":"59","author":"van der Gali\u00ebn","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01783-16","article-title":"Pharmacokinetic modeling and limited sampling strategies based on healthy volunteers for monitoring of ertapenem in patients with multidrug-resistant tuberculosis","volume":"61","author":"van Rijn","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib49","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American thoracic society\/centers for disease Control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.tube.2023.102367_bib50","first-page":"3","article-title":"What is the 'right' dose of rifampin?","volume":"7","author":"Peloquin","year":"2003","journal-title":"Int J Tubercul Lung Dis"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib51","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/520011","article-title":"Stability of antituberculosis drugs mixed in food","volume":"45","author":"Peloquin","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.tube.2023.102367_bib52","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib53","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1128\/AAC.02599-12","article-title":"Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients","volume":"57","author":"Tostmann","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib54","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1086\/431984","article-title":"Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana","volume":"41","author":"Tappero","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib55","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118-2124.2003","article-title":"Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib56","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.01550-06","article-title":"Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients","volume":"51","author":"Ruslami","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.tube.2023.102367_bib57","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1093\/cid\/cir184","article-title":"Why do we use 600 mg of rifampicin in tuberculosis treatment?","volume":"52","author":"van Ingen","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib58","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/tpj.2016.26","article-title":"Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients","volume":"17","author":"Ben Fredj","year":"2017","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tube.2007.05.012","article-title":"Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis","volume":"87","author":"Cho","year":"2007","journal-title":"Tuberculosis"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2165\/00003088-197904060-00001","article-title":"Clinical pharmacokinetics of isoniazid","volume":"4","author":"Weber","year":"1979","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.tube.2023.102367_bib61","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1164\/ajrccm.155.5.9154882","article-title":"Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis","volume":"155","author":"Parkin","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.tube.2023.102367_bib62","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1378\/chest.113.5.1178","article-title":"Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients","volume":"113","author":"Kimerling","year":"1998","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.tube.2023.102367_bib63","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1164\/rccm.200208-951OC","article-title":"Tuberculosis Trials Consortium. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine","volume":"167","author":"Weiner","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.tube.2023.102367_bib64","doi-asserted-by":"crossref","first-page":"e3520","DOI":"10.1093\/cid\/ciaa1569","article-title":"Drug exposure and minimum inhibitory concentration predict pulmonary tuberculosis treatment response","volume":"73","author":"Zheng","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2023.102367_bib65","series-title":"Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RRTB)","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.tube.2023.102367_bib66","series-title":"Treatment guidelines of drug-resistant tuberculosis","author":"World Health Organization","year":"2016"},{"issue":"S3","key":"10.1016\/j.tube.2023.102367_bib67","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000057839","article-title":"Comparison of side effects of levofloxacin versus other fluoroquinolones","volume":"47","author":"Carbon","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.tube.2023.102367_bib68","series-title":"Guidelines for treatment of tuberculosis","author":"World Health Organization","year":"2010"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S2213-2600(18)30078-X","article-title":"Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis","volume":"6","author":"Fregonese","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.tube.2023.102367_bib70","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/jac\/dkw164","article-title":"Pharmacokinetic\/pharmacodynamic-based optimization of levofloxacin administration in the treatment of MDR-TB","volume":"71","author":"Ghimire","year":"2016","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.tube.2023.102367_bib71","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/17425255.2016.1162785","article-title":"Current status and opportunities for therapeutic drug monitoring in the treatment of tuberculosis","volume":"12","author":"Zuur","year":"2016","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib72","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1183\/09031936.00073213","article-title":"Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment?","volume":"42","author":"Srivastava","year":"2013","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.tube.2023.102367_bib73","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1473-3099(17)30449-8","article-title":"Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science","volume":"17","author":"Alffenaar","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tube.2023.102367_bib74","series-title":"Annex 2. Weight-based dosing of drugs for adults. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update","first-page":"20","author":"World Health Organization","year":"2008"},{"issue":"11","key":"10.1016\/j.tube.2023.102367_bib75","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.tube.2023.102367_bib76","first-page":"622","article-title":"Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis","volume":"6","author":"de Jager","year":"2002","journal-title":"Int J Tubercul Lung Dis"},{"issue":"suppl_3","key":"10.1016\/j.tube.2023.102367_bib77","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1093\/cid\/ciy624","article-title":"D-cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a faustian deal","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.tube.2023.102367_bib78","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/AAC.01549-13","article-title":"Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis","volume":"58","author":"Mpagama","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.tube.2023.102367_bib79","doi-asserted-by":"crossref","first-page":"931","DOI":"10.5588\/ijtld.17.0648","article-title":"Therapeutic drug monitoring of cycloserine and linezolid during anti-tuberculosis treatment in Beijing, China","volume":"22","author":"Zhu","year":"2018","journal-title":"Int J Tubercul Lung Dis"},{"issue":"1","key":"10.1016\/j.tube.2023.102367_bib80","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jac\/dki148","article-title":"Linezolid for the treatment of multidrug-resistant tuberculosis","volume":"56","author":"Fort\u00fan","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.tube.2023.102367_bib81","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jinf.2005.04.007","article-title":"Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)-a report of ten cases","volume":"52","author":"von der Lippe","year":"2006","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib82","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1128\/AAC.50.4.1599-1602.2006","article-title":"Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients","volume":"50","author":"Bishop","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.tube.2023.102367_bib83","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4046\/trd.2015.78.2.78","article-title":"Outcomes and use of therapeutic drug monitoring in multidrug-resistant tuberculosis patients treated in Virginia, 2009-2014","volume":"78","author":"Heysell","year":"2015","journal-title":"Tuberc Respir Dis"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib84","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1183\/13993003.00606-2015","article-title":"Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study","volume":"46","author":"Bolhuis","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib85","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"issue":"6","key":"10.1016\/j.tube.2023.102367_bib86","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.tube.2023.102367_bib87","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1183\/13993003.01654-2015","article-title":"Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis","volume":"47","author":"van Rijn","year":"2016","journal-title":"Eur Respir J"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979223000653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979223000653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:46:56Z","timestamp":1761468416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979223000653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":87,"alternative-id":["S1472979223000653"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2023.102367","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2023.102367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102367"}}